New BASS Sponsor Cialis(R) (tadalafil) Showcases Interactive Presence in Augusta
2005年3月2日 - 11:00PM
PRニュース・ワイアー (英語)
New BASS Sponsor Cialis(R) (tadalafil) Showcases Interactive
Presence in Augusta -- Cialis Boat, Truck and Relaxation Tent
Headline On-Site Activities -- AUGUSTA, Ga., March 2
/PRNewswire-FirstCall/ -- Cialis(R) (tadalafil), the erectile
dysfunction drug marketed by Lilly ICOS
(NYSE:LLYNYSE:andNYSE:Nasdaq:NYSE:ICOS), is unveiling its full
sponsorship program today at the Bassmaster Tournament Trail event
being held at the J. Strom Thurmond Reservoir. The Cialis-branded
boat made an auspicious debut at the season-opener in Kissimmee,
Fla. when Takahiro Omori, the defending CITGO Bassmaster Classic
champion, chose the Cialis bass boat on the final two days of
competition to claim victory and the $100,000 winner's purse. Fans
on-site at the reservoir can experience the various innovative
elements as part of the premiere sponsorship by Cialis: *
Exhibition Tent: Spectators in Augusta can experience the
"Bassmaster University presented by Cialis" tent, which will be
stocked with interactive fishing-related activities and seminars
with expert anglers. Highlights from ESPN2's Bassmaster University
show will also be featured in the Cialis tent. * Relaxation Center:
One designated area in front of the weigh-in will be branded
"Relaxation Center presented by Cialis." The relaxing atmosphere
will be designed to help spectators unwind and enjoy close-up views
of the weigh-in. Cialis will have a strong signage presence at the
event, including boat, truck and driver uniform signage. "During
this exciting Bassmaster Tournament Trail event, we hope that fans
and anglers will experience the on-site activities that were
designed to help enhance relaxation and enjoyment of the sport of
bass fishing," said Matt Beebe, Cialis U.S. Brand Team Leader.
"BASS members are an important audience to us. Our alliance with
BASS allows us to reach a targeted fan base that enjoys bass
fishing because it's both relaxing and exhilarating." For those
fans watching from home, Cialis is involved in the action via
television and the Web site: * Bassmaster University: Cialis is the
presenting sponsor of Bassmaster University for the entire 2005
season. This includes opening and closing credits on each episode
as well as a weekly "Cialis Angler's Ready List" that highlights
fishing equipment needed for each lesson. An online Bassmaster
University page will link to http://www.cialis.com/ . Bassmaster
University airs on BASS Saturday at 9:30 a.m. ET/PT and 8:30 a.m.
CT on ESPN2. * Interactive Web Site: Angling fans everywhere can
soon visit http://www.bassmaster.com/ to experience many of the
innovative elements of the Cialis BASS sponsorship, including tips
for relaxing and improving their fishing skills. Cialis BASS
Sponsorship As part of the one-year agreement, Cialis will have a
major interactive presence at the majority of BASS events,
including the CITGO Bassmaster Tour, the Bassmaster Elite 50 Series
and the CITGO Bassmaster Classic. For Lilly ICOS, the BASS
sponsorship represents a unique opportunity to educate men in the
United States about a significant health issue -- erectile
dysfunction (ED) -- and the role of Cialis as the only oral ED
treatment shown to improve erectile function for up to 36 hours in
most men. Through its partnership with BASS, Lilly ICOS offers
consumers information about ED and Cialis. Consumers may pick up
brochures on ED or Cialis at the tents, and visit the Cialis Web
site, http://www.cialis.com/ , to get more information about
Cialis. Available by prescription, Cialis was approved by the U.S.
Food & Drug Administration on November 21, 2003. About BASS
BASS is the world's largest fishing organization, sanctioning more
than 20,000 tournaments worldwide through its Federation. The CITGO
Bassmaster Tournament Trail, which includes the exciting Bassmaster
Elite 50 series, is the oldest and most prestigious pro bass
fishing tournament circuit and continues to set the standard for
credibility, professionalism and sportsmanship as it has since
1968. For more information, contact BASS Communications at (334)
551-2375 or visit http://www.bassmaster.com/ . About Cialis Cialis,
approved by the FDA in November 2003 for the treatment of erectile
dysfunction, is the only oral ED treatment shown to improve
erectile function up to 36 hours in most men. Cialis can be taken
without regard to food. The absorption of Cialis is not reduced by
food, including high-fat foods. Cialis is currently available in
approximately 100 countries, including Australia, Brazil, Mexico,
Canada, the United States and countries throughout Europe. More
than 3.5 million patients worldwide have been treated with Cialis
since its first introduction in February 2003. Cialis is available
by prescription only and is not for everyone. Men taking nitrates,
often used for chest pain, or certain alpha-blockers for prostate
problems or high blood pressure, should not take Cialis. Such
combinations could cause a sudden, unsafe drop in blood pressure.
Men should discuss their health status with their doctors to ensure
Cialis is right for them and that they are healthy enough for
sexual activity. The most common side effects with Cialis were
headache, upset stomach, delayed backache or muscle ache. Although
rare, men who experience an erection for more than four hours
should seek immediate medical attention. Men should not drink
alcohol in excess with Cialis. Cialis does not protect a man or his
partner from sexually transmitted diseases, including HIV.
Individual results may vary. Cialis studies were not designed to
assess multiple intercourse attempts after a single dose. For full
patient information, visit http://www.cialis.com/ . About Lilly
ICOS LLC Lilly ICOS LLC, a joint venture between ICOS Corporation
(NASDAQ:ICOS) and Eli Lilly and Company (NYSE:LLY), developed
tadalafil for the treatment of erectile dysfunction. ICOS
Corporation, a biotechnology company headquartered in Bothell,
Washington, is dedicated to bringing innovative therapeutics to
patients. ICOS is marketing its product, Cialis (tadalafil),
through Lilly ICOS LLC. ICOS is working to develop treatments for
serious unmet medical conditions such as chronic obstructive
pulmonary disease, benign prostatic hyperplasia, cancer and
inflammatory diseases. Lilly, a leading innovation-driven
corporation is developing a growing portfolio of first-in-class and
best-in-class pharmaceutical products by applying the latest
research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered
in Indianapolis, Ind., Lilly provides answers -- through medicines
and information -- for some of the world's most urgent medical
needs. Additional information about Lilly is available at
http://www.lilly.com/ . P-LLY Except for historical information
contained herein, this press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements are based on
current expectations, estimates and projections about the industry,
management beliefs and certain assumptions made by the management
of ICOS and Lilly. Investors are cautioned that matters subject to
forward-looking statements involve risks and uncertainties,
including economic, competitive, governmental, technological, legal
and other factors discussed in the two companies' respective
filings with the Securities and Exchange Commission, which may
affect the business and prospects of the two companies and Lilly
ICOS. Results and the timing and outcome of events may differ
materially from those expressed or implied by the forward-looking
statements in this press release. More specifically, there can be
no assurance that Cialis will achieve commercial success or that
competing products will not pre-empt market opportunities that
might exist for the product. Cialis(R) is a registered trademark of
Lilly ICOS LLC. Other trademarks are the property of their
respective owners. (Logo:
http://www.newscom.com/cgi-bin/prnh/20040122/LILLYICOSLOGO )
http://www.newscom.com/cgi-bin/prnh/20040122/LILLYICOSLOGO
DATASOURCE: Lilly ICOS LLC CONTACT: Kindra Strupp of Lilly ICOS,
+1-317-277-5170; or Jamie Wilkinson of BASS, +1-334-551-2457
Copyright